ASCO publishes a suite of peer-reviewed journals with content focused on

  • clinical oncology research;
  • issues and insights affecting oncology practice;
  • cancer care, research and care delivery issues unique to countries and settings with limited healthcare resources;
  • biomedical informatics methods and processes applied to cancer-related data, information, and images; and
  • the science and practice of precision oncology.

ASCO’s peer-reviewed journals follow a continuous publication schedule. Below is a select list of the newest content from ASCO’s journals. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Email ASCO’s Media Team to request an embargoed journal article or an interview with a study author.

ASCO occasionally highlights select journal articles in an embargoed press release known as a News Digest or in a Featured Article summary. Sign up to receive communications regarding these articles.

Publishing September 17, 4:00 p.m. ET:

Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country (JGO: Original Report)
Tiago Andreis, et al.
Request this article

Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome (JCO PO: Original Report)
Fergus Couch, et al.
Request this article

Atypical RAS Mutations in Metastatic Colorectal Cancer (JCO PO: Original Report)
Filippo Pietrantonio, et al.
Request this article

Publishing September 16, 4:00 p.m. ET:

Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial (JCO: Original Report)
Woo Chul Noh, et al.
Request this article

Association Between Power Morcellation and Mortality in Women With Unexpected Uterine Cancer Undergoing Hysterectomy or Myomectomy (JCO: Original Report)
Xiao Xu, et al.
Request this article

Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma (JCO PO: Original Report)
Matthias Fischer, et al.
Request this article

Publishing September 12, 4:00 p.m. ET:

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study (JCO: Original Report)
Jean Donadieu, et al.
Request this article

Bevacizumab or Temsirolimus for First Relapse Rhabddomyosarcoma (JCO: Original Report)
Leo Mascarenhas, et al.
Request this article

Microsatellite Instability in Resectable Gastric Cancer (JCO: Original Report)
Elizabeth Smyt, et al.
Request this article

Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non–Small-Cell Lung Cancer (JOP: Original Contribution)
Scott Ramsey, et al.
Request this article

Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient Outcomes (JCO PO: Special Article)
Jerome Jourquin, et al.
Request this article

Publishing September 11, 4:00 p.m. ET:

Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis (JCO: Original Report)
Mohamad Jawhar, et al.
Request this article

Practice-Level Adoption of Conservative Management for Prostate Cancer (JOP: Original Contribution)
Parth Modi, et al.
Request this article

Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non–Small-Cell Lung Cancer With Liver Metastases (JOP: Original Contribution)
William Wong, et al.
Request this article

“My Family Wants Something Different”: Discordance in Perceived Personal and Family Treatment Preference and Its Association With Do-Not-Resuscitate Order Placement (JOP: Original Contribution)
Login George, et al.
Request this article

Publishing September 10, 4:00 p.m. ET:

Positron Emission Tomography–Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group (JCO: Original Report)
Andreas Engert, et al.
Request this article

Publishing September 09, 4:00 p.m. ET:

Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer(JCO PO: Original Report)
Adam Sowalsky, et al.
Request this article

Publishing September 05, 4:00 p.m. ET:

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial (JCO: Original Report)
Robert Naumann, et al.
Request this article

Treatment of Wilms Tumor in Sub-Saharan Africa: Results of the Second French African Pediatric Oncology Group Study (JGO: Original Report)
Catherine Patte, et al.
Request this article

Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network (JCO CCI: Special Article)
Andrea Burnett-Hartman, et al.
Request this article

The embargo date and time of a journal article coincide with its online publication date and time. Journalists may conduct embargoed interviews with study authors up to one week prior to the online publication date. ASCO takes embargo violations seriously and violations typically result in the loss of journal media privileges for a period of one year and may affect broader ASCO media privileges as well. Journalists may request embargoed articles. Please direct further questions regarding the embargo policies for ASCO Journals to the Media Team.